Healthcare Business

Why Credit Suisse Prefers Johnson & Johnson Over Pfizer

Major pharmaceutical companies have posted a relatively positive year so far. Currently, Johnson & Johnson (NYSE: JNJ) is leading the pack with Eli Lilly and Co. (NYSE: LLY) a close ...
Read Full Story »

Vertex Wins Big in Mid-Stage Cystic Fibrosis Trial

Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) saw its shares make an incredible gain on Wednesday after the company announced results from its early and mid-stage trials in cystic fibrosis (CF). The ...
Read Full Story »

SunTrust Says Big Pharmaceuticals Have Multiple Catalysts for the Rest of 2017

Healthcare, which struggled mightily during the brutal election season last year and even back into 2015, has had a nice first half of 2017. Given the current nosebleed levels of ...
Read Full Story »

Gilead Secures FDA Approval For Chronic Hepatitis C Re-Treatment

Gilead Sciences, Inc. (NASDAQ: GILD) shares remained unchanged after the firm announced an approval from the U.S. Food and Drug Administration (FDA). Essentially, the FDA approved Vosevi (sofosbuvir 400 mg/velpatasvir ...
Read Full Story »

Puma Biotech Wins Big on FDA Approval of Breast Cancer Treatment

 Shares of Puma Biotechnology, Inc. (NASDAQ: PBYI) touched a multiyear high Tuesday after the company reported a key approval by the U.S. Food and Drug Administration (FDA). Specifically, the agency ...
Read Full Story »

Johnson & Johnson Shares Slip Following Mixed Earnings

Johnson & Johnson (NYSE: JNJ) released its fiscal second-quarter earnings report before the markets opened on Tuesday. The company posted $1.83 in earnings per share (EPS) on $18.8 billion in ...
Read Full Story »

Why UnitedHealth’s Second-Quarter Profits Weren’t Enough

UnitedHealth Group Inc. (NYSE: UNH) reported second-quarter 2017 results before markets opened Tuesday morning. The health insurance and benefits management company reported adjusted diluted quarterly earnings per share (EPS) of ...
Read Full Story »

Sienna Biopharma Closes In on IPO

Sienna Biopharmaceuticals filed an amended S-1 form with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO). The company expects to price its 4.33 million shares ...
Read Full Story »

Apollo Endosurgery Gears Up for Secondary Offering

Apollo Endosurgery Inc. (NASDAQ: APEN) saw its shares slide on Friday after the company announced terms of its secondary offering. The firm filed an amended S-1 form with the U.S. ...
Read Full Story »

Short Sellers Hike Bets in Major Biotechs

The short interest data are out for the most recent settlement date, June 30. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, ...
Read Full Story »

Major Pharma Short Sellers Become More Selective

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Why Ocular Therapeutix Shares Are Getting Crushed

Ocular Therapeutix Inc. (NASDAQ: OCUL) shares were absolutely crushed on Wednesday after the firm received less than favorable news from the U.S. Food and Drug Administration (FDA). In effect, the ...
Read Full Story »

PetIQ Announces Potential Pricing for IPO

PetIQ has filed an amended S-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO). The company intends to price its 5.67 million shares ...
Read Full Story »

Meet Jefferies Top 12 Picks in the Roaring Biotech Industry

The biotech industry has made a splash in 2017, outperforming practically all the broad markets. With this incredible display, it's no wonder that investor interest in this particular industry has ...
Read Full Story »

Why Arena Pharmaceuticals Is Knocking It Out of the Park

Shares of Arena Pharmaceuticals Inc. (NASDAQ: ARNA) saw an incredible gain early Tuesday after the company reported positive results from its mid-stage trial in patients with pulmonary arterial hypertension (PAH). ...
Read Full Story »